LENZ Therapeutics (LENZ) Preferred Stock Liabilities (2020 - 2023)

LENZ Therapeutics' (LENZ) quarterly Preferred Stock Liabilities came in at $143.4 million in Q4 2023, up 221.35% on a QoQ basis from $44.6 million in Q3 2023.

LENZ Therapeutics (LENZ) Preferred Stock Liabilities (2020 - 2023) Analysis & Trends

LENZ Therapeutics (LENZ) has 3 years of Preferred Stock Liabilities data on file, last reported at $143.4 million in Q4 2023.

  • On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $143.4 million in Q4 2023; TTM through Dec 2023 was $143.4 million, a N/A change from a year earlier, with the FY2023 full-year figure at $143.4 million, changed N/A from the prior year.
  • Preferred Stock Liabilities for Q4 2023 stood at $143.4 million, up from $44.6 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for LENZ reached as high as $143.4 million in Q4 2023 and fell as low as $9.9 million in Q2 2023.
  • Historically, Preferred Stock Liabilities has averaged $53.9 million across 3 years, with a median of $44.6 million in 2023.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 LENZ Therapeutics 158.34 Mn 158.34 Mn 825,000.00 -

Historic Data

Download Data
DateValue
Dec 31, 2023 143.39 Mn
Sep 30, 2023 44.62 Mn
Jun 30, 2023 9.89 Mn
Mar 31, 2023 44.62 Mn
Mar 31, 2021 110.01 Mn
Dec 31, 2020 55.61 Mn
Sep 30, 2020 11.51 Mn
Jun 30, 2020 11.51 Mn